of patients with lupus taking BENLYSTA preferred
administration with the Autoinjector over IV infusion.1,2*

IV = intravenous; SC = subcutaneous; SLE = systemic lupus erythematosus.

* A follow-up survey was conducted in patients with SLE (N=43) who completed an open-label, multi-dose, usability, tolerability, and safety study of SC belimumab where they were switched from IV or prefilled syringe belimumab to self-administered doses using the autoinjector for 8 weekly doses. Patients (n=42) were asked, “What is your preference for receiving BENLYSTA: using the autoinjector or IV?” 


BENLYSTA IV comes in two
vial sizes and is administered
as a 10-mg/kg dose.
For more
information about ordering
Gateway at

Picture: 120 mg single-dose vial of BENLYSTA

120-mg in a 5-mL
single-dose vial

(NDC 49401-0101-01)

Picture: 400 mg single-dose vial of BENLYSTA

400-mg in a 20-mL
single-dose vial

(NDC 49401-0102-01)

Vial Calculator

PATIENT {{patientNumber}}
Remove x
mg (10 mg/kg)

* One of these fields is required

Reconstituted Solution for Dilution
0 mL
Recommended Vial Combination
120-mg vials
400-mg vials
0 mg
Icon: Calendar With One Check Mark

Enter the weight or dose for each patient and see the results below.


    • Reconstitute BENLYSTA IV using aseptic technique.
    • Remove BENLYSTA IV from the refrigerator and allow to stand 10 to 15 minutes for the vial(s)
      to reach room temperature.
    • Reconstitute BENLYSTA IV powder with Sterile Water for Injection, USP, as follows.
      The reconstituted solution will contain a concentration of 80 mg/mL belimumab. Use of a 21-
      to 25-gauge needle is recommended.
      • Reconstitute the 120-mg vial with 1.5 mL Sterile Water for Injection, USP
      • Reconstitute the 400-mg vial with 4.8 mL Sterile Water for Injection, USP
    • The stream of sterile water should be directed toward the side of the vial to minimize foaming.
    • Reconstitution is typically complete within 10 to 15 minutes after the sterile water has been
      added, but it may take up to 30 minutes.
    • Protect the reconstituted solution from direct sunlight.
    • Once reconstitution is complete, the solution should be opalescent and colorless to pale yellow
      and without particles. Small air bubbles are expected and acceptable.
    • If a mechanical reconstitution device (swirler) is used, it should not exceed 500 rpm and the vial
      swirled for no longer than 30 minutes.
    • The reconstituted solution of BENLYSTA IV, if not used immediately, should be stored protected
      from direct sunlight and refrigerated at 36° to 46°F (2° to 8°C).
    • The total time from reconstitution of BENLYSTA IV to completion of infusion should not exceed
      8 hours.
Icon: IV vial

Swirl, don't shake

Remember that when reconstituting BENLYSTA IV, you must swirl – not shake – the vial.

  • Allow the vial to sit at room
    temperature during reconstitution.
  • Gently swirl the vial for 60 seconds
    every 5 minutes until the powder
    is dissolved.
Icon: IV bag

Prepare the infusion

The reconstituted BENLYSTA IV must be diluted. Calculate the volume required to
be added to the infusion bag using this formula:

__-mg dose ÷ 80 mg/mL =
__mL to be added to infusion bag


    818-mg dose ÷ 80 mg/mL = 10.2 mL to be added to infusion bag

    • Dextrose intravenous solutions are incompatible with BENLYSTA IV. BENLYSTA IV should only
      be diluted in 0.9% Sodium Chloride Injection, USP (normal saline) or 0.45% Sodium Chloride
      Injection, USP (half normal saline) or Lactated Ringer’s Injection, USP to a volume of 250 mL
      for intravenous infusion.
      • For patients whose body weight is ≤40 kg, 100 mL may be used such that the resulting
        belimumab concentration in the infusion bag does not exceed 4 mg/mL.
    • From the 250-mL infusion bag or bottle, withdraw and discard a volume of fluid equal to the
      volume of reconstituted solution of BENLYSTA required for the patient’s dose.
    • Add the required volume of the reconstituted solution of BENLYSTA IV to the bag or bottle,
      and then gently invert to mix.
    • Inspect solution for particulate matter and discoloration prior to administration and discard
      if either is observed.
    • Any unused solution in the vials must be discarded.
    • Diluted solutions of BENLYSTA IV may be stored at 36° to 46°F (2° to 8°C) or room temperature.
    • Remember, the total time from reconstitution of BENLYSTA IV to completion of infusion should
      not exceed 8 hours.

    The diluted solution should be administered as an intravenous infusion and given over a 1-hour period.

    • Do not administer as an
      intravenous push or bolus.
    • Consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions prior to
      IV dosing. However, there is insufficient evidence to
      determine whether premedication diminishes the frequency or severity of hypersensitivity reactions.
    • BENLYSTA IV should be administered by healthcare providers prepared to manage anaphylaxis
      or other infusion reactions.
    • BENLYSTA should not be infused concomitantly in the same intravenous line with other agents.

Talk to your
patients about
the most
dosing option
for them